A COMPARATIVE STUDY ON THERAPEUTIC RESPONSE AND SURVIVAL TIME OF PATIENTS WITH MULTIPLE MYELOMA TREATED WITH MODIFIED VMCP RE

ＡＣＯＭＰＡＲＡＴＩＶＥＳＴＵＤＹＯＮＴＨＥＲＡＰＥＵＴＩＣＲＥＳＰＯＮＳＥＡＮＤＳＵＲＶＩＶＡＬＴＩＭＥＯＦＰＡＴＩＥＮＴＳＷＩＴＨ　ＭＵＬＴＩＰＬＥＭＹＥＬＯＭＡＴＲＥＡＴＥＤ　ＷＩＴＨ　ＭＯＤＩＦＩＥＤＶＭＣＰＲＥＧＩＭＥＮＣｈｅｎＸｕｅｍｉｎ...

A COMPARATIVE STUDY ON THERAPEUTIC RESPONSE AND SURVIVAL TIME OF PATIENTS WITH MULTIPLE MYELOMA TREATED WITH MODIFIED VMCP REGIMEN

Therapeutic response and survival time or 43 patients with multiple myeloma treated with modified VMCP(Vincristine,Melphalan, Cyelophosphamide and perdnisone;mVMCP)multidrug regimen are analyzed,and compared with those of 41 patients treated with VACP, M2, MP and other regimens.Therapeutic response to mVMCP regimen was better than that to other combination regimens(83. 5% VS 60.9%;P< 0.01).The median remission duration in patients responding to mVMCP was longer than that to other regimens(18.7 vs 12.2 mouths;P<0.001).But the survival time of two groups of responders was not signifficautly different(32. 5 vs 34.1 mouths; P>0.5).The prognostic significance of various pretreatment characteristics was evaluated in term of therapeutic response.The bone status and renal function had a significant inverse correlation with the survival time of patients responding to chemotherapy.Our data indicate that the patients with MM treated by mean or mVMCP regimen can obtain a better response in early treatment and maintain a longer remission duration as well as a better performance status. although the regimen can not prolong the patients survival time.